Home/Filings/4/0001415889-23-010291
4//SEC Filing

Rosen Howard B 4

Accession 0001415889-23-010291

CIK 0001479419other

Filed

Jun 22, 8:00 PM ET

Accepted

Jun 23, 8:00 PM ET

Size

13.0 KB

Accession

0001415889-23-010291

Insider Transaction Report

Form 4
Period: 2023-06-22
Transactions
  • Award

    Common Stock

    2023-06-22+7,98811,387 total
  • Award

    Common Stock

    2023-06-22+1,10012,487 total
  • Award

    Stock Option (right to buy)

    2023-06-22+10,65110,651 total
    Exercise: $14.56Exp: 2033-06-21Common Stock (10,651 underlying)
  • Award

    Stock Option (right to buy)

    2023-06-22+2,5002,500 total
    Exercise: $14.56Exp: 2033-06-21Common Stock (2,500 underlying)
Holdings
  • Common Stock

    (indirect: See Footnote)
    165
Footnotes (7)
  • [F1]Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 1/3 of the shares underlying the RSUs on June 22, 2024, as to 1/3 of the shares underlying the RSUs on June 22, 2025 and as to the final 1/3 of shares underlying the RSUs on June 22, 2026.
  • [F2]Includes 11,290 unvested RSUs.
  • [F3]Grant of RSUs under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 22, 2024 or (ii) the date of the first annual meeting following June 22, 2023.
  • [F4]Includes 12,390 unvested RSUs.
  • [F5]These shares are owned directly by the Rosen/Doherty Revocable Trust Dated 6/11/01 (the "Trust"), and indirectly by Mr. Rosen as co-trustee of the Trust.
  • [F6]This option was granted on June 22, 2023 and vests over four years beginning on the vesting commencement date of June 22, 2023, with 25% of the shares underlying the option vesting on June 22, 2024, and an additional 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter.
  • [F7]This option was granted on June 22, 2023 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 22, 2024 or (ii) the date of the first annual meeting following June 22, 2023.

Issuer

Kala Pharmaceuticals, Inc.

CIK 0001479419

Entity typeother

Related Parties

1
  • filerCIK 0001307068

Filing Metadata

Form type
4
Filed
Jun 22, 8:00 PM ET
Accepted
Jun 23, 8:00 PM ET
Size
13.0 KB